FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  MILLENNIUM PHARMACEUTICALS INC
 2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2017		 3. Issuer Name and Ticker or Trading Symbol
Molecular Templates, Inc. [MTEM]
(Last)
(First)
(Middle)
40 LANDSDOWNE STREET		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CAMBRIDGE, MA 02139		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2,922,993
D (1)
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
MILLENNIUM PHARMACEUTICALS INC
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139		     X    
Takeda Pharmaceuticals International AG
THURGAUERSTRASSE 130, 8152
GLATTPARK, V8 		     X    
Takeda Pharma A/S
LANGEBJERG 1, 4000
ROSKILDE, G7 		     X    
Takeda A/S
DYBENDAL ALLE 10, 2630
TAASTRUP, G7 		     X    
Takeda Europe Holdings B.V.
JUPITERSTRAAT 250, 2132 HK
HOOFDDORP, P7 		     X    
TAKEDA PHARMACEUTICAL CO LTD
12-10, NIHONBASHI 2-CHOME, CHUO-KU
TOKYO, M0 103-8668		     X    
Takeda Pharmaceuticals U.S.A., Inc.
ONE TAKEDA PARKWAY
DEERFIELD, IL 60015		     X    

Signatures

/s/ James Kehoe, Chief Financial Officer, Takeda Pharmaceutical Company Limited 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Millennium Pharmaceuticals, Inc. 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Takeda Pharmaceuticals U.S.A., Inc. 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Takeda Pharmaceutical International AG 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Takeda Pharma A/S 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Takeda A/S 09/08/2017
**Signature of Reporting Person Date
/s/ Brett R. Budzinski, Attorney-in-Fact for Takeda Europe Holdings B.V. 09/08/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These shares are owned directly by Millennium Pharmaceuticals, Inc. ("Millennium"). Millennium is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc. ("Takeda USA"). Takeda Pharmaceutical Company Limited ("Takeda") owns 73.37% of Takeda USA, and Takeda Pharmaceuticals International AG ("Takeda International") owns 26.63% of Takeda USA. Takeda Pharma A/S ("Takeda Denmark") owns 86.83% of Takeda International, and Takeda Europe Holdings B.V. ("Takeda Europe") owns 13.17% of Takeda International. Takeda Denmark is a wholly-owned direct subsidiary of Takeda A/S. Takeda owns 76.09% of Takeda A/S, and Takeda Europe owns 23.91% of Takeda A/S. Takeda Europe is a wholly-owned direct subsidiary of Takeda. Takeda, Takeda USA, Takeda International, Takeda Denmark, Takeda A/S and Takeda Europe each disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.
 
Remarks:
Exhibit List: Exhibit 24.1 Power of Attorney for Millennium Pharmaceuticals, Inc.; Exhibit 24.2 Power of Attorney for Takeda Pharmaceuticals U.S.A., Inc.; Exhibit 24.3 Power of Attorney for Takeda Pharmaceuticals International AG; Exhibit 24.4 Power of Attorney for Takeda Pharma A/S; Exhibit 24.5 Power of Attorney for Takeda A/S; Exhibit 24.6 Power of Attorney for Takeda Europe Holdings B.V.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.